Evidence map›Paper›PMID 33267852›Full record

ArticleBMC medical informatics and decision making2020

Cognitive biomarker prioritization in Alzheimer's Disease using brain morphometric data.

Bo Peng, Xiaohui Yao, Shannon L Risacher, Andrew J Saykin, Li Shen, Xia Ning, ADNI

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bo PengThe Ohio State University, Columbus, USA.
Xiaohui YaoUniversity of Pennsylvania, Philadelphia, USA.
Shannon L RisacherIndiana University, Indianapolis, USA.
Andrew J SaykinIndiana University, Indianapolis, USA.
Li ShenUniversity of Pennsylvania, Philadelphia, USA.
Xia NingThe Ohio State University, Columbus, USA. ning.104@osu.edu.ORCID 0000-0002-6842-1165
ADNI

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Memory Circuitry in MCI and Early Alzheimer’s Disease Prodrome: Molecular DriversR01AG019771 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 2001 to 2021
$6.9M
Integrative Bioinformatics Approaches to Human Brain Genomics and ConnectomicsR01EB022574 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI SHEN, LI · 2016 to 2019
$1.9M
NIA NIH HHS P30 AG010133NIA NIH HHS R01 AG019771NIA NIH HHS U01 AG024904NIBIB NIH HHS R01 EB022574
6 · The paper itself

Abstract

backgroundCognitive assessments represent the most common clinical routine for the diagnosis of Alzheimer's Disease (AD). Given a large number of cognitive assessment tools and time-limited office visits, it is important to determine a proper set of cognitive tests for different subjects. Most current studies create guidelines of cognitive test selection for a targeted population, but they are not customized for each individual subject. In this manuscript, we develop a machine learning paradigm enabling personalized cognitive assessments prioritization.

methodWe adapt a newly developed learning-to-rank approach [Formula: see text] to implement our paradigm. This method learns the latent scoring function that pushes the most effective cognitive assessments onto the top of the prioritization list. We also extend [Formula: see text] to better separate the most effective cognitive assessments and the less effective ones.

resultsOur empirical study on the ADNI data shows that the proposed paradigm outperforms the state-of-the-art baselines on identifying and prioritizing individual-specific cognitive biomarkers. We conduct experiments in cross validation and level-out validation settings. In the two settings, our paradigm significantly outperforms the best baselines with improvement as much as 22.1% and 19.7%, respectively, on prioritizing cognitive features.

conclusionsThe proposed paradigm achieves superior performance on prioritizing cognitive biomarkers. The cognitive biomarkers prioritized on top have great potentials to facilitate personalized diagnosis, disease subtyping, and ultimately precision medicine in AD.

Indexed as

Alzheimer DiseaseBiomarkersBrainCognitionCognitive DysfunctionComputational BiologyHumansImage Interpretation, Computer-AssistedMachine LearningMagnetic Resonance ImagingBiomarkersAlzheimer’s DiseaseBioinformaticsLearning to rankMachine learning

Identifiers

PMID33267852
PMCPMC7709267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.